Hepatitis B vaccination: Disease and cancer prevention-A taiwanese experience

Clinics in Liver Disease

Volumn 14, Issue 3, 2010, Pages 521-530

  Chang, Mei Hwei ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Hepatitis B immunoglobulin; Hepatitis B surface antigen; Hepatitis B vaccination; Hepatitis B virus; Hepatocellular carcinoma

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN;

ACTIVE IMMUNIZATION; CANCER PREVENTION; DRUG EFFICACY; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOPROPHYLAXIS; INFECTION CONTROL; LIVER CELL CARCINOMA; NONHUMAN; PASSIVE IMMUNIZATION; PATIENT COMPLIANCE; REVIEW; TAIWAN; VACCINATION; CARCINOMA, HEPATOCELLULAR; COMPLICATION; DISEASE MANAGEMENT; DISEASE OUTBREAKS; DRUG EFFECTS; ECONOMICS; FEMALE; FORECASTING; HEPATITIS B VIRUS; IMMUNOLOGY; LIVER NEOPLASMS; MALE; NEWBORN; PHYSIOLOGY; PREGNANCY; PREVENTION AND CONTROL; PREVENTIVE HEALTH SERVICE; PROCEDURES; TRENDS; VERTICAL TRANSMISSION;

CARCINOMA, HEPATOCELLULAR; DISEASE MANAGEMENT; DISEASE OUTBREAKS; FEMALE; FORECASTING; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION, PASSIVE; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; LIVER NEOPLASMS; MALE; PREGNANCY; TAIWAN; VACCINATION;

EID: 77954640226     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2010.05.010     Document Type: Review

References (48)

1. Ganem D., Prince A.M. Hepatitis B virus infection natural history and clinical consequences. N Engl J Med 2004, 350:1118-1129.
2. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004, 11:97-107.
3. Chang M.H. Prospects for hepatitis B virus eradication and control of hepatocellular carcinoma. Baillieres Clin Gastroenterol 2000, 13:511-517.
4. Hsu H.Y., Chang M.H., Chen D.S., et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986, 18:301-307.
5. Feret E., Larouze B., Dip B., et al. Epidemiology of hepatitis B virus infection in the rural community of Tip, Senegal. Am J Epidemiol 1987, 125:140-149.
6. Stevens C.E., Beasley R.P., Tsui J., et al. Vertical transmission of hepatitis B antigen in Taiwan. N Engl J Med 1975, 292:771-774.
7. Hsu S.C., Chang M.H., Ni Y.H., et al. Horizontal transmission of HBV in children. J Pediatr Gastroenterol Nutr 1993, 16:66-69.
8. Beasley R.P., Hwang L.Y., Lin C.C., et al. Incidence of hepatitis B virus infection in preschool children in Taiwan. J Infect Dis 1982, 146:198-204.
9. Beasley R.P., Hwang L.Y., Stevens C.E., et al. Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology 1983, 3:135-141.
10. Lee G.C., Hwang L.Y., Beasley R.P., et al. Immunogenicity of hepatitis B vaccine in healthy Chinese neonates. J Infect Dis 1983, 148:526-529.
11. Chen D.S., Hsu N.H., Sung J.L., et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987, 257:2597-2603.
12. Shepard C.W., Simard E.P., Finelli L., et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006, 28:112-125.
13. Poovorawan Y., Theamboonlers A., Vimolket T., et al. Impact of hepatitis B immunization as part of the EPI. Vaccine 2000, 19:943-949.
14. Tsen Y.J., Chang M.H., Hsu H.Y., et al. Seroepidemiology of hepatitis B virus infection in Taipei, 1989-Five years after a mass hepatitis B vaccination program. J Med Virol 1991, 34:96-99.
15. Chen H.L., Chang M.H., Ni Y.H., et al. Seroepidemiology of hepatitis B virus infection in children-ten years of mass vaccination in Taiwan. J Am Med Assoc 1996, 276:906-908.
16. Ni Y.H., Chang M.H., Huang L.M., et al. Hepatitis B virus infection in children and adolescents in a hyperendemic area: 15 years after mass hepatitis B vaccination. Ann Intern Med 2001, 135:796-800.
17. Ni Y.H., Huang L.M., Chang M.H., et al. Two decades of universal hepatitis B vaccination in Taiwan: impact and implication for future strategies. Gastroenterology 2007, 132:1287-1293.
18. Whittle H.C., Maine N., Pilkington J., et al. Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet 1995, 29(345):1089-1092.
19. Jang M.K., Lee J.Y., Lee J.H., et al. Seroepidemiology of HBV infection in South Korea, 1995 through 1999. Korean J Intern Med 2001, 16:153-159.
20. Chang M.H., Lee C.Y., Chen D.S., et al. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr 1987, 111:34-39.
21. Kao J.H., Hsu H.M., Shau W.Y., et al. Universal hepatitis B vaccination and the decreased mortality from fulminant hepatitis in infants in Taiwan. J Pediatr 2001, 139:349-352.
22. Chen H.L., Chang C.J., Kong M.S., et al. Fulminant hepatic failure in children in endemic area of hepatitis B virus infection: 15 years after universal hepatitis B vaccination. Hepatology 2004, 39:58-63.
23. Chang M.H., Chen D.S., Hsu H.C., et al. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989, 64:2377-2380.
24. Chang M.H., Chen P.J., Chen J.Y., et al. Hepatitis B virus integration in hepatitis B virus related hepatocellular carcinoma in childhood. Hepatology 1991, 13:316-320.
25. Chang M.H., Chen C.J., Lai M.S., et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997, 336:1855-1859.
26. Chang M.H., Shau W.Y., Chen C.J., et al. The effect of universal hepatitis B vaccination on hepatocellular carcinoma rates in boys and girls. JAMA 2000, 284:3040-3042.
27. Chang M.H., Chen J., Hsu H.M., et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005, 11:7953-7957.
28. Chang M.H., You S.L., Chen C.J., et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009, 101:1348-1355.
29. Lu C.Y., Ni Y.H., Chiang B.L., et al. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008, 197:1419-1426.
30. Lu C.Y., Chiang B.L., Chi W.K., et al. Waning immunity to plasma-derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology 2004, 40:1415-1420.
31. Lin Y.C., Chang M.H., Ni Y.H., et al. Long-term immunogenicity and efficacy of universal hepatitis B virus vaccination in Taiwan. J Infect Dis 2003, 187:134-138.
32. Wang C.W., Wang L.C., Chang M.H., et al. Long-term follow-up of hepatitis B surface antibody levels in subjects receiving universal hepatitis B vaccination in infancy in an area of hyperendemicity: correlation between radioimmunoassay and enzyme immunoassay. Clin Diagn Lab Imunol 2005, 12:1442-1447.
33. McMahon B.J., Dentinger C.M., Bruden D., et al. Antibody levels and protection after hepatitis B vaccine: results of a 22-year follow-up study and response to a booster dose. J Infect Dis 2009, 200:1390-1396.
34. Poovorawan Y., Chongsrisawat V., Theamboonlers A., et al. Long-term benefit of hepatitis B vaccination among children in Thailand with transient hepatitis B virus infection who were born to hepatitis B surface antigen-positive mothers. J Infect Dis 2009, 200:33-38.
35. Su W.J., Ho M.C., Ni Y.H., et al. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection. J Pediatr Gastroenterol Nutr 2009, 48:203-208.
36. Lee S.D., Lo K.J., Wu J.C., et al. Prevention of maternal-infant hepatitis B virus transmission by immunization: the role of serum hepatitis B virus DNA. Hepatology 1986, 6:369-373.
37. Tang J.R., Hsu H.Y., Lin H.H., et al. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998, 133:374-377.
38. Lin H.H., Lee T.Y., Chen D.S., et al. Transplacental leakage of HBeAg-positive maternal blood as the most likely route in causing intrauterine infection with hepatitis B virus. J Pediatr 1987, 111:877-881.
39. Hsu H.Y., Chang M.H., Liaw S.H., et al. Changes of hepatitis B surface variants in carrier children before and after universal vaccination in Taiwan. Hepatology 1999, 30:1312-1317.
40. Hsu H.Y., Chang M.H., Ni Y.H., et al. Survey of hepatitis B surface variant infection in children 15 years after nationwide vaccination program in Taiwan. Gut 2004, 53:1499-1503.
41. Hsu H.Y., Chang M.H., Ni Y.H., et al. Twenty-year trends in the emergence of hepatitis B surface antigen variants in children and adolescents after universal vaccination in Taiwan. J Infect Dis 2010, 201:1192-1200.
42. Halsey N.A., Duclos P., van Damme P., et al. Hepatitis B vaccine and central nervous system demyelinating diseases. Viral Hepatitis Prevention Board. Pediatr Infect Dis J 1999, 18:23-24.
43. WHO Report on the Expanded Program on Immunization (EPI) of the World Health Organisation (WHO) Department of Vaccines and Biologicals. (Post-exposure immunization for hepatitis B) Available at:, Accessed December 15, 2009. http://www.who.immunization.
44. Beasley R.P. Rocks along the road to the control of HBV and HCC. Ann Epidemiol 2009, 19:231-234.
45. Van Herck K., Vorsters A., Van Damme P. Prevention of viral hepatitis (B and C) reassessed. Best Pract Res Clin Gastroetenrol 2008, 22:1009-1029.
46. Lavanchy D. Chronic viral hepatitis as a public health issue in the world. Best Pract Res Clin Gastroenterol 2008, 22:991-1008.
47. Van Zonneveld M., van Nunen A.B., Niesters H.G.M., et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003, 10:294-297.
48. Xu W.M., Cui Y.T., Wang L., et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16:94-103.